Skip to main content
. 2021 Apr-Jun;13(2):70–78. doi: 10.32607/actanaturae.11031

Table.

Clinical trials of drugs targeting GBA-PD

Drug Pharmacological group Mechanism Phase
Ambroxol Pharmacological chaperone Activation of GCase II
Venglustat (GZ/SAR402671) Substrate reduction therapy A decrease in the substrate concentration (inhibition of glucosylceramide synthase) II
LTI-291 Pharmacological chaperone Allosteric activator of GCase Ib